Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.
Hamdy, Neveen A T
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. [electronic resource] - Current opinion in investigational drugs (London, England : 2000) Apr 2007 - 299-303 p. digital
Publication Type: Journal Article; Review
1472-4472
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Denosumab
Humans
Injections, Subcutaneous
Osteoporosis--drug therapy
RANK Ligand
Receptor Activator of Nuclear Factor-kappa B--immunology
Signal Transduction--drug effects
Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis. [electronic resource] - Current opinion in investigational drugs (London, England : 2000) Apr 2007 - 299-303 p. digital
Publication Type: Journal Article; Review
1472-4472
Animals
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Denosumab
Humans
Injections, Subcutaneous
Osteoporosis--drug therapy
RANK Ligand
Receptor Activator of Nuclear Factor-kappa B--immunology
Signal Transduction--drug effects